Canada’s Drug Agency | Drugs, Health Technologies and Systems.

Search

Filters

No filters applied.

Showing 21 - 30 results of 2188

Download as CSV

upadacitinib (Rinvoq) (Last Updated: Jun 2, 2025)

Project Line:
Reimbursement Review
Project Status:
Active
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Rinvoq
Manufacturer:
AbbVie Corporation
Submission Type:
Initial
Indications:

RINVOQ is indicated for the treatment of adult patients with giant cell arteritis (GCA). RINVOQ is used in combination with corticosteroids and as monotherapy following discontinuation of corticosteroids.

durvalumab (Imfinzi) (Last Updated: May 30, 2025)

Project Line:
Reimbursement Review
Project Status:
Active
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Imfinzi
Manufacturer:
AstraZeneca Canada Inc.
Submission Type:
Initial
Indications:

​Imfinzi (durvalumab) is currently under review by Health Canada for the following proposed indication: for the treatment of patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following platinum-based chemoradiation therapy (CRT).

durvalumab, tremelimumab (Imfinzi, Imjudo ) (Last Updated: May 30, 2025)

Project Line:
Reimbursement Review
Project Status:
Active
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Imfinzi, Imjudo
Manufacturer:
AstraZeneca Canada Inc.
Submission Type:
Initial
Indications:

​Imfinzi in combination with tremelimumab and
platinum-based chemotherapy is indicated for the first-line treatment of
patients with metastatic NSCLC with no sensitizing epidermal growth factor
receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic tumour
aberrations.

Newborn Screening for Metachromatic Leukodystrophy (Last Updated: May 29, 2025)

As a part of the Government of Canada’s National Strategy for Drugs for Rare Diseases, Canada’s Drug Agency supported the development of pan-Canadian guidance for newborn screening. The overall goal...

Project Line:
Health Technology Review
Project Status:
Active

Long-Acting Inhaled Drugs for Chronic Obstructive Pulmonary Disease (Last Updated: May 29, 2025)

Chronic obstructive pulmonary disease (COPD) involves progressive airway obstruction and inflammation. COPD inhalation treatments aim to prevent exacerbations, alleviate respiratory symptoms, and...

Project Line:
Health Technology Review
Project Status:
Active

Pharmaceutical Reviews Update — Issue 56 () (Last Updated: May 29, 2025)

Program Updates 1. Further Streamlining the Tailored Review Process Since the launch of the Pharmaceuticals With Anticipated Comparable Efficacy and Safety (PACES) process in February 2025, we...

Project Line:
Reimbursement Review

Acute Lymphoblastic Leukemia () (Last Updated: May 29, 2025)

Review Type: Rapid Provisional Funding Algorithm Scope posting: 12-Dec-24 Stakeholder Input Deadline: 10-Feb-25 Draft Report Posted : 29-May-25 Stakeholder Feedback Deadline : 9-Jun-25 Final Report...

Project Line:
Reimbursement Review
Project Status:
Open for Feedback

vamorolone (Agamree) (Last Updated: May 29, 2025)

Project Line:
Reimbursement Review
Project Status:
Pending
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Agamree
Manufacturer:
Kye Pharmaceuticals Inc.
Submission Type:
Initial
Indications:

​For the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older.

This site uses cookies to provide you with a better user experience, analyzing Web traffic and trends and making overall site improvements.  You can find out more information and how to change some cookie settings in our privacy policy / Give me more information